Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paroxetine controlled release.

Lynne M Bang1, Gillian M Keating

  • 1Adis International Limited, Auckland, New Zealand.

CNS Drugs
|April 20, 2004
PubMed
Summary
This summary is machine-generated.

A new controlled-release paroxetine formulation effectively treats depression, social anxiety, PMDD, and panic disorder. This selective serotonin reuptake inhibitor (SSRI) offers improved tolerability, notably reduced nausea compared to immediate-release versions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Gastroenterology

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are mainstays in treating various psychiatric disorders.
  • Paroxetine, an SSRI, has established efficacy but can be associated with side effects like nausea.
  • Controlled-release (CR) formulations aim to improve drug delivery and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a novel controlled-release (CR) formulation of paroxetine.
  • To compare the adverse event profile of paroxetine CR with immediate-release paroxetine, focusing on nausea.

Main Methods:

  • Placebo-controlled trials were conducted in patients diagnosed with major depressive disorder, social anxiety disorder, premenstrual dysphoric disorder (PMDD), and panic disorder.

Related Experiment Videos

  • Efficacy was assessed using validated scales such as the Hamilton Rating Scale for Depression, Liebowitz Social Anxiety Scale, and Clinical Global Impressions-Global Improvement score.
  • Treatment durations varied, including 12 weeks for depression and anxiety disorders, and three menstrual cycles for PMDD.

    • Main Results:

    • Paroxetine CR demonstrated consistent superiority over placebo in primary endpoints across all studied conditions (major depressive disorder, social anxiety disorder, PMDD, panic disorder).
    • The CR formulation was generally well tolerated, exhibiting a typical SSRI adverse-event profile.
    • Significantly less nausea was reported in patients receiving paroxetine CR compared to immediate-release paroxetine during the first week of treatment.

    Conclusions:

    • The controlled-release formulation of paroxetine is an effective treatment option for major depressive disorder, social anxiety disorder, PMDD, and panic disorder.
    • Paroxetine CR offers a favorable tolerability profile, with a notable reduction in early-treatment nausea compared to the immediate-release version.
    • This CR formulation represents a valuable advancement in SSRI therapy, potentially improving patient compliance and experience.